What are the ESMO guidelines on genetic risk assessment for ovarian cancer?

Updated: Aug 10, 2020
  • Author: Andrew E Green, MD; Chief Editor: Yukio Sonoda, MD  more...
  • Print

Guidelines from ESMO, updated in 2016, note that testing criteria differ between countries based on the population prevalence of the mutation and include not only specific criteria very similar to that of NCCN, but also more general criteria such as having a 10-20% probability of finding a mutation based on predictive models, or the assumption of a potential benefit in the medical or surgical management of the individual or close family members. [127]

Overall, ESMO recommends that all patients referred for BRCA testing first complete informed consent and genetic counseling and that those who are mutation carriers be encouraged to advise close family members to obtain genetic counseling. [127]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!